Stockscreener 앱 받기
22.60
2.31%
0.51
시간 외 거래:
22.60
전일 마감가:
$22.09
열려 있는:
$22.26
하루 거래량:
1.46M
Relative Volume:
0.88
시가총액:
$3.87B
수익:
$1.10B
순이익/손실:
$375.65M
주가수익비율:
10.29
EPS:
2.1963
순현금흐름:
$113.59M
1주 성능:
+7.93%
1개월 성능:
+7.11%
6개월 성능:
-18.79%
1년 성능:
+0.53%
1일 변동 폭
$22.01
$22.66
1주일 범위
$20.92
$22.66
52주 변동 폭
$19.69
$28.35
Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile
명칭
Acadia Pharmaceuticals Inc
전화
858-558-2871
주소
12830 EL CAMINO REAL, SAN DIEGO
Compare ACAD vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ACAD
Acadia Pharmaceuticals Inc
|
22.60 | 3.70B | 1.10B | 375.65M | 113.59M | 2.1963 |
VRTX
Vertex Pharmaceuticals Inc
|
468.42 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
618.03 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.40 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
288.20 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
169.51 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-25 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2026-02-24 | 개시 | Wolfe Research | Outperform |
| 2026-02-23 | 업그레이드 | Mizuho | Neutral → Outperform |
| 2025-10-21 | 개시 | Citigroup | Buy |
| 2025-05-21 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2025-02-11 | 개시 | Deutsche Bank | Hold |
| 2025-01-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-10-10 | 재개 | Raymond James | Mkt Perform |
| 2024-08-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-27 | 개시 | BMO Capital Markets | Outperform |
| 2024-03-12 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2024-03-12 | 재확인 | Needham | Buy |
| 2024-01-30 | 개시 | Robert W. Baird | Outperform |
| 2024-01-24 | 업그레이드 | Needham | Hold → Buy |
| 2023-12-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-14 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2023-12-13 | 개시 | Citigroup | Buy |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-11-06 | 업그레이드 | Mizuho | Neutral → Buy |
| 2023-10-17 | 개시 | UBS | Buy |
| 2023-10-10 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-01-03 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-11-04 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-11-01 | 개시 | Loop Capital | Hold |
| 2022-08-08 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-08-05 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-06-21 | 다운그레이드 | Jefferies | Buy → Underperform |
| 2022-06-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-03-16 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2022-02-09 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2022-01-05 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-12-21 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-11-01 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2021-10-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | 재개 | Needham | Hold |
| 2021-06-10 | 개시 | Berenberg | Hold |
| 2021-04-07 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2021-04-06 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2021-04-06 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-04-06 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-04-06 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2021-04-05 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2021-03-10 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-03-09 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-03-09 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-03-09 | 재확인 | H.C. Wainwright | Buy |
| 2021-03-09 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2021-03-09 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-12-16 | 개시 | Mizuho | Buy |
| 2020-11-16 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2020-08-25 | 개시 | Raymond James | Outperform |
| 2020-08-20 | 개시 | Morgan Stanley | Overweight |
| 2020-07-07 | 업그레이드 | Stifel | Hold → Buy |
| 2020-04-16 | 개시 | Jefferies | Buy |
| 2020-03-31 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-03-06 | 개시 | Citigroup | Buy |
| 2019-12-16 | 개시 | Guggenheim | Buy |
| 2019-10-24 | 개시 | Oppenheimer | Perform |
| 2019-10-01 | 개시 | RBC Capital Mkts | Outperform |
| 2019-09-13 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-10 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2019-07-23 | 재확인 | Needham | Buy |
| 2018-12-10 | 개시 | Canaccord Genuity | Hold |
| 2018-09-21 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2018-08-09 | 재확인 | Stifel | Hold |
| 2018-08-07 | 개시 | Stifel | Hold |
| 2018-08-06 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2017-10-06 | 재개 | Goldman | Neutral |
모두보기
Acadia Pharmaceuticals Inc 주식(ACAD)의 최신 뉴스
ACADIA Pharmaceuticals (ACAD) Stock Could Be 23.2% Undervalued After Guidance Reaffirmed - simplywall.st
ACADIA Pharmaceuticals Inc (ACAD) Institutional Confidence - TradingKey
ACADIA Pharmaceuticals Inc (ACAD) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ACADIA Pharmaceuticals strategy under review, shares tracked against biotech peers - AD HOC NEWS
ACADIA Pharmaceuticals: The Song Remains The Same (NASDAQ:ACAD) - Seeking Alpha
ACADIA Pharmaceuticals Inc (ACAD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Aardvark Therapeutics Becomes Next Pharma Player To Quit Prader-Willi Syndrome Drug Development Efforts - Stocktwits
How Investors May Respond To ACADIA Pharmaceuticals (ACAD) ESOP-Linked Shelf Registration And Potential Dilution - simplywall.st
ACADIA Pharmaceuticals Inc (ACAD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
ACADIA Pharmaceuticals Inc (ACAD) Valuation: PE, PB & Fair Value Analysis - TradingKey
ACADIA Pharmaceuticals Inc (ACAD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ACADIA Pharmaceuticals Inc (ACAD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ACADIA Pharmaceuticals Inc - TradingKey
ACADIA Pharmaceuticals Inc (ACAD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Precision Trading with Acadia Pharmaceuticals Inc. (ACAD) Risk Zones - Stock Traders Daily
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Parkinson’s Support Group Meeting Friday, June 12, In Warsaw - InkFreeNews.com
ACADIA Pharmaceuticals stock (US0042251084): earnings momentum and pipeline focus in neuroscience - AD HOC NEWS
Acadia Pharma Must Face Investors' Drug Approval Claims - Law360
A Look At ACADIA Pharmaceuticals (ACAD) Valuation As Shares Show Mixed Recent Momentum - simplywall.st
ACADIA Pharmaceuticals stock (US0042251084): focus on Neurology and rare disease pipeline after late - AD HOC NEWS
A Look At ACADIA Pharmaceuticals (ACAD) Valuation After Recent Share Price Weakness - Yahoo Finance
ACADIA Pharmaceuticals spotlights Alzheimer's psychosis pipeline, NUPLAZID and DAYBUE growth - MSN
Earnings call transcript: ACADIA Pharmaceuticals misses Q1 2026 EPS forecast - Investing.com
Acadia Pharmaceuticals Inc (ACAD) News, Articles, Events & Latest Updates - Stocktwits
ACADIA Pharmaceuticals earnings up next: Can drug sales sustain momentum? - Investing.com
ACADIA Stock Climbs After Hours as Biotech Rally Shifts Focus to Its Next Big Drug Readout - Bez Kabli
ACAD Technical Analysis | Trend, Signals & Chart Patterns | ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) - ChartMill
Baker funds tied to ACAD (ACAD) report RSU and stock option grants - Stock Titan
Technical Reactions to ACAD Trends in Macro Strategies - Stock Traders Daily
ACAD Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
ACADIA Pharmaceuticals (ACAD) director receives new RSUs and stock option grant - Stock Titan
ACADIA (NASDAQ: ACAD) director Adora Ndu exercises RSUs and receives new option, RSU grants - Stock Titan
ACADIA (NASDAQ: ACAD) director receives RSUs and $21.66 stock options - Stock Titan
ACADIA (NASDAQ: ACAD) director granted RSUs, options and exercises into shares - Stock Titan
ACADIA (ACAD) director Garofalo exercises RSUs and receives new option, RSU awards - Stock Titan
ACADIA (NASDAQ: ACAD) director granted RSUs and stock options - Stock Titan
Acadia Shareholders Approve Directors, Executive Pay and Equity Plan - The Globe and Mail
A Quick Look at Today's Ratings for ACADIA Pharmaceuticals(ACAD.US), With a Forecast Between $24 to $38 - Moomoo
Acadia Pharmaceuticals (NASDAQ: ACAD) investors approve 5.2M-share boost to 2024 equity plan - Stock Titan
Principal Accounting Officer At ACADIA Pharmaceuticals Sells $114K Of Stock - Benzinga
Biopharmas look to China, elsewhere for partnerships, R&D - MSN
Insider Sell: James Kihara Sells Shares of ACADIA Pharmaceuticals Inc (ACAD) - GuruFocus
Acadia principal accounting officer Kihara sells $114,393 stock - Investing.com UK
[Form 4] ACADIA PHARMACEUTICALS INC Insider Trading Activity - Stock Titan
ACADIA Pharmaceuticals (ACAD) Holds Near Support as Price Action ConsolidatesDiagonal Spread Trade - thelegaladvocate.com
ACADIA Pharmaceuticals targets $1B brand opportunity as key neuropsychiatry data looms - MSN
Form 144 lists 3,857 performance shares and ESPP lots for ACAD (NASDAQ: ACAD) - Stock Titan
Acadia Pharmaceuticals (ACAD) lags Q1 earnings and revenue estimates - MSN
Acadia boosts ‘More To Parkinson's’ campaign with Ryan Reynolds, Parkinson’s voices - Fierce Pharma
Acadia Pharmaceuticals’ SWOT analysis: stock faces EU hurdle By Investing.com - Investing.com Canada
Acadia Pharmaceuticals Inc (ACAD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.48%
자본화:
|
볼륨(24시간):